Key result
Historically marginalized breast cancer patients face higher CV mortality, greater cardiotoxicity, and reduced care access.
Why the study?
The dual burden of breast cancer and CVD is unevenly distributed across racial, socioeconomic, and geographic groups, but how social and structural factors drive these disparities requires synthesis.
This review highlights significant social and structural disparities in cardio-oncology outcomes among breast cancer survivors and emphasizes the need for equitable care strategies.
May warrant social determinants screening in cardio-oncology; leaves open targeted equity interventions for breast cancer patients.
Breast cancer and cardiovascular disease (CVD) increasingly coexist as a major source of morbidity and mortality among survivors. As cancer survival improves, cardiovascular complications have emerged as a leading determinant of long-term outcomes, often exceeding cancer-related mortality. This dual disease burden is unevenly distributed, with marked disparities across race and ethnicity, socioeconomic status, geographic location, comorbid risk burden, and representation in clinical trials. Evidence demonstrates that historically marginalized populations experience higher cardiovascular mortality, greater treatment-related cardiotoxicity, and reduced access to preventive and specialty care. This review synthesizes current literature on cardio-oncology disparities and applies established frameworks-including intersectionality, structural racism, and syndemic theory-to explain how social and structural factors translate into adverse clinical outcomes. We highlight emerging clinical, community-based, and policy-level strategies aimed at promoting equitable cardiovascular survivorship for breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Obeidat et al. (2026) conducted a review in Breast cancer and cardiovascular disease. Social and structural factors was evaluated. Historically marginalized populations with breast cancer experience higher cardiovascular mortality, greater treatment-related cardiotoxicity, and reduced access to preventive and specialty care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: